Person:
KORTEN, VOLKAN

Profile Picture

Email Address

Birth Date

Research Projects

Organizational Units

OrgUnit Logo
Organizational Unit

Job Title

Last Name

KORTEN

First Name

VOLKAN

Name

Filters

2001 - 20089
Reset filters

Settings

End date: 2009 × Start date: 2000 ×

Search Results

Now showing 1 - 9 of 9
  • No Thumbnail Available
    PublicationMetadata only
    Susceptibility of bacterial isolates from Turkey - A report from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program
    (TAYLOR & FRANCIS LTD, 2007) KORTEN, VOLKAN; Eraksoy, H.; Basustaoglu, A.; Korten, V.; Kurt, H.; Ozturk, R.; Ulusoy, S.; Yaman, A.; Yuce, A.; Zarakolu, P.
    The study monitored the susceptibility of nosocomial pathogens to meropenem and comparator antimicrobial agents isolated as part of the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program from Turkish university hospitals. In terms of minimum inhibitory concentration 90% (MIC90) values, meropenem was two- and eight-fold more active than imipenem against Escherichia coli and Klebsiella pneumoniae, respectively. 40.5% of K. pneumoniae, 23.1% of Klebsiella oxytoca and 15.3% of E. coli isolates were extended-spectrum P-lactamase (ESBL) producers. Piperacillin/tazobactam was the most active agent against isolates of Pseudomonas aeruginosa, followed by meropenem and imipenem. Against Acinetobacter baumannii isolates, meropenem and imipenem were the most active agents. Continued surveillance by the MYSTIC Program appears to be prudent to help focus on effective empiric treatment regimens.
  • No Thumbnail Available
    PublicationOpen Access
    Crimean-Congo Hemorrhagic Fever in Turkey
    (2004-08) KORTEN, VOLKAN; Karti, S. Sami; Odabasi, Zekaver; Korten, Volkan; Yilmaz, Mustafa; Sonmez, Mehmet; Caylan, Rahmet; Akdogan, Elif; Eren, Necmi; Koksal, Iftihar; Ovali, Ercument; Erickson, Bobbie R.; Vincent, Martin J.; Nichol, Stuart T.; Comer, James A.; Rollin, Pierre E.; Ksiazek, Thomas G.
  • No Thumbnail Available
    PublicationMetadata only
  • Thumbnail Image
    PublicationOpen Access
    Vancomycin versus Placebo for Treating Persistent Fever in Patients with Neutropenic Cancer Receiving Piperacillin-Tazobactam Monotherapy
    (2003-08-01) KORTEN, VOLKAN; Cometta, A.; Kern, W. V.; De Bock, R.; Paesmans, M.; Vandenbergh, M.; Crokaert, F.; Engelhard, D.; Marchetti, O.; Akan, H.; Skoutelis, A.; Korten, V.; Vandercam, M.; Gaya, H.; Padmos, A.; Klastersky, J.; Zinner, S.; Glauser, M. P.; Calandra, T.; Viscoli, C.; The International Antimicrobial Therapy Group of the European Organization for Research Treatment of Cancer
  • No Thumbnail Available
    PublicationMetadata only
    Antibiotic resistance surveillance over a 4-year period (2000-2003) in Turkey: results of the MYSTIC Program
    (ELSEVIER SCIENCE INC, 2007) KORTEN, VOLKAN; Korten, Volkan; Ulusoy, Sercan; Zarakolu, Pinar; Mete, Birgul
    The Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program is a global study that provides antimicrobial susceptibility data in centers prescribing meropenem. The activity of meropenem and 7 broad-spectrum antimicrobials have been examined against 5208 bacterial isolates from 9 Turkish centers between 2000 and 2003. Cumulative susceptibility rates against all species of Enterobacteriaceae combined were ranked as follows: meropenem (99.3%), imipenem (97.6%), cefepime (80.0%), piperacillin-tazobactam (73.6%), ceftazidime (70.3%), ciprofloxacin (70.1%), cefotaxime (66.9%), and tobramycin (67.2%). The production of extended-spectrum beta-lactamases (ESBLs) was detected in 48.7% of Klebsiella pneumoniae and in 19.5% of Escherichia coli isolates. Of ESBL producing K. pneumoniae isolates, 75.7% were resistant to tobramycin, 40.3% to ciprofloxacin, and 48.3% to piperacillin-tazobactam. Only piperacillin/ tazobactam and carbapenems were active against more than 50% of Pseudomonas aeruginosa at the National Committee for Clinical Laboratory Standards-susceptible breakpoint, and the carbapenems were the most active compounds against Acinetobacter spp. These data confirm the continued potency of meropenem against Enterobacteriaceae in units where it is actively being prescribed. (c) 2007 Elsevier Inc. All rights reserved.
  • Thumbnail Image
    PublicationOpen Access
    An unusual native tricuspid valve endocarditis caused by Candida colliculosa
    (BLACKWELL PUBLISHING LTD, 2003-04) DURMUŞOĞLU, LÜTFİYE; Kaygusuz, I; Mulazimoglu, L; Cerikcioglu, N; Toprak, A; Oktay, A; Korten, V
    Candida colliculosa , which grew in blood cultures of a 71-year-old retired man with fever of unknown origin that had lasted for 7 months, in conjunction with transthoracic echocardiography, demonstrating a 20-mm vegetation, superior to the tricuspid valve, herniating into the right atrial cavity. The finding led to the diagnosis of fungal endocarditis. Fluconazole, 600 mg daily, was commenced for 8 days; followed by amphotericin B, 1 mg/kg daily. On the fourth day of the amphotericin B treatment, the patient underwent replacement of the infected tricuspid valve. Even though the initial postoperative period was relatively uncomplicated, the patient died after a gross aspiration on the 67th day of his hospital stay, despite aggressive cardiovascular support and antimicrobial therapy. This is the first report of a native tricuspid valve fungal endocarditis due to C. colliculosa or Torulaspora delbrueckii , which is not known to be a human pathogen.
  • Thumbnail Image
    PublicationOpen Access
    Increasing carbapenem resistance due to the clonal dissemination of oxacillinase (OXA-23 and OXA-58)-producing Acinetobacter baumannii: report from the Turkish SENTRY Program sites
    (MICROBIOLOGY SOC, 2008-12-01) KORTEN, VOLKAN; Gur, Deniz; Korten, Volken; Unal, Serhat; Deshpande, Lalitagauri M.; Castanheira, Mariana
    A significant increase in carbapenem-resistance rates among Acinetobacter baumannii isolates collected in two Turkish medical centres was detected in the 2000-2006 period (20-60%) by the SENTRY Antimicrobial Surveillance Program. Carbapenem-resistant strains from 2006 were evaluated for the presence of encoding genes and epidemic clonality. OXA-58-like and OXA-23-like carbapenemase-producing strains were detected in both medical institutions. Seventeen out of 18 strains from Ankara were positive for bla(OXA-58) primers and belonged to the same clone, whilst 26 isolates (25 from Istanbul and one from Ankara) harboured bla(OXA-23)-like genes and showed identical or similar PFGE patterns. Isolates producing OXA-23-like carbapenemases were more resistant than OXA-58-like carbapenemase producers to non-carbapenem antimicrobial agents. Carbapenem resistance in these institutions was observed to be largely driven by the dissemination of clones producing OXA-type carbapenemases.
  • Thumbnail Image
    PublicationOpen Access
    STREPTOCOCCUS BOVIS ENDOCARDITIS ASSOCIATED WITH RECTAL CARCINOMA AND ITS NEUROLOGICAL COMPLICATIONS CASE REPORT AND LITERATURE REVIEW
    (2006-04-15) KORTEN, VOLKAN; Abul, Yasin; Odabasi, Zekaver; Kodalli, Nihat; Oktay, Ahmet; Korten, Volkan
  • No Thumbnail Available
    PublicationMetadata only
    Comparison of cefepime and ceftazidime in combination with amikacin in the empirical treatment of high-risk patients with febrile neutropenia: A prospective, randomized, multicenter study
    (TAYLOR & FRANCIS AS, 2001) KORTEN, VOLKAN; Erman, M; Akova, M; Akan, H; Korten, V; Ferhanoglu, B; Koksal, I; Cetinkaya, Y; Uzun, O; Unal, S
    A total of 208 adult patients with cancer and febrile neutropenia from 5 medical institutions were randomized to receive either cefepime (2 g b.i.d.) or ceftazidime (2 g t.i.d.) in combination with amikacin (15 mg/kg/o.d.). Ninety-seven patients in the ceftazidime (CEZ) group and 98 in the cefepime group (CEF) were evaluable for efficacy. In 68 patients (35%), infection could be documented. The average duration of antibiotic therapy was 11 and 12 d and response rates to the empirical regimen were 36 and 30% for the CEZ and CEF groups, respectively (p>0.05). The average time of defervescence in responders was 3 d for both groups. Modification of the initial regimen with antivirals and/or azole antifungals raised the number of responders to 44% and 35%, respectively (p>0.05). Vancomycin was additionally given to 29 patients in the CEZ group and to 27 patients in the CEF group. Twenty-six patients in each group received empirical amphotericin B. Mild, reversible study drug-related side-effects were observed in 12 patients (12%) in the CEZ group and 13 patients (13%) in the CEF group (p>0.05). Cefepime in combination with amikacin seems to be as effective, safe and tolerable as ceftazidime + amikacin in patients with high-risk neutropenia and fever.